SCHEMBL5509658

SCHEMBL5509658

COc1cc(C=C2SC(=O)NC2=O)ccc1OCc1ccc(F)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
IGF1R P08069 2/20 0.64
PIM1 P11309 1/20 0.61
PDE4B Q07343 1/20 0.61
PIM3 Q86V86 1/20 0.61
PIM2 Q9P1W9 1/20 0.61
FOXM1 Q08050 1/20 0.58
ESRRA P11474 2/20 0.56
ADAMTS5 Q9UNA0 1/20 0.56
PTPN1 P18031 2/20 0.55
HPGD P15428 4/20 0.55
MGAM O43451 1/20 0.55
GAA P10253 1/20 0.55
SI P14410 1/20 0.55
MGAM2 Q2M2H8 1/20 0.55
CISD1 Q9NZ45 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5509654 1.00 MEN1 (0.64) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL21637670 0.90 IGF1R (0.68) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL13479549 0.90 IGF1R (0.68) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL5504182 0.82 MEN1 (0.79) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL5504181 0.82 MEN1 (0.79) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL5504480 0.80 ALDH1A1 (0.64) MEN1KMT2AHPGDGAA
SCHEMBL2697203 0.80 ESRRA (0.75) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL2697205 0.80 ESRRA (0.75) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL5508722 0.78 MEN1 (1.00) MEN1KMT2AIGF1RPIM1PDE4B
SCHEMBL5508719 0.78 MEN1 (1.00) MEN1KMT2AIGF1RPIM1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781271-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP claimed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 WO claimed
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-19 US claimed
EP-1781271-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 WO disclosed
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers ESR2, ESRRG, GPER1 MEN1 4702/4885KMT2A 1285/4885IGF1R 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.